Author's response to reviews
|
|
- Felix Fisher
- 5 years ago
- Views:
Transcription
1 Author's response to reviews Title: Vital capacity and inspiratory capacitiy as additional parameters to evaluate bronchodilator response in asthmatics patients: a cross section study Authors: Karen S Azevedo (karensodre@hotmail.com) Ronir R Luiz (ronir@iesc.ufrj.br) Patricia RM Rocco (prmrocco@biof.ufrj.br) Marcus B Conde (marcusconde@hucff.ufrj.br) Version: 2 Date: 28 June 2012 Author's response to reviews: see over
2 June 28 th, 2012 Dear Prof. Timothy Shipley MS: : Vital capacity and inspiratory capacity as additional parameters to evaluate bronchodilator response in asthmatics patients: a cross section study. Thank you very much for the opportunity to revise our submission to BMC Pulmonary Medicine. The text has been carefully revised according to the reviewers suggestions. We would like to express our gratitude to the assessors; their thorough work really helped us improve the manuscript. We hope that in its present form the paper can be accepted for publication in BMC Pulmonary Medicine. Karen S. Azevedo, MD. Chief, Laboratory of Pulmonary Function Test Institute of Thoracic Diseases Federal University of Rio de Janeiro Tel/fax: marcusconde@hucff.ufrj.br
3 Reviewer 1: Reviewer's report Title: Vital capacity and inspiratory capacitiy as additional parameters to evaluate bronchodilator response in asthmatics patients: a cross section study Version: 1 Date: 13 March 2012 Reviewer: Christophe Delclaux Reviewer's report: The aim of this study was to evaluate the usefulness of vital capacity and inspiratory capacity to evaluate bronchodilator response in asthma patients with persistent airflow obstruction. Clearly, the evaluation of bronchodilator response deserves to be studied in these patients. Thank you very much for your comments. Major comments 1. Why were the patients divided into two small groups, based on non consensual cutoff levels of FEV1? The ATS/ERS consensus defines severity of any spirometric abnormality based on the FEV1: Mild <70, Moderate 60 69, Moderately severe 50 59, Severe and Very severe <35% predicted. The authors should at least justify their choice based on a pathophysiological background. We agree with your comment. However, we divided the patients into 2 groups based on GINA (2006, the year we started collect these data) that classified severity based on clinics data and on cut-off levels of FEV1: moderate (60%<FEV1<80%) and severe (FEV1 60%). Furthermore, it has already been suggested that higher degree of obstruction is associated with more hyperinflation and consequently an increase volume response after bronchodilators. Based on this aforementioned we analyzed if the response in VC and IC was more intense in patients with severe obstruction compared to moderate. We justified our choice in the test, as suggested by the reviewer. 2. The effect of treatments on resting dyspnea is a difficult issue. Most patients with severe obstruction do not complain of resting dyspnea usually, and it has been shown that perceived effect of treatment is mainly related to the increase in forced inspiratory flows (Taube C, AJRCCM, 2000). I m surprised by the baseline resting values of Borg scores given in Table 2 that seems quite elevated (VAS instead of Borg?, please clarify). The authors state that the gold standard for clinical bronchodilator response was 6MWD # 50 meters or at least 30 meters associated with a reduction greater than 2 points in the Borg scale score. They would better state that they defined clinical bronchodilator response as because in ref 23 the distance was 54 meters (95% CI: 37 to 71 m) and the ref 5 is not available in PubMed. Moreover, the well-demonstrated learning effect of 6MWT should have been at least discussed (ideally patients should have two 6MWT before bronchodilation, this limitation should be discussed). Tel/fax: marcusconde@hucff.ufrj.br
4 We agree with the reviewer that the effect of treatments on resting dyspnea is a difficult issue. In fact, in patients with severe airway obstruction it has been reported that FEV1 presents a lack of sensitivity to evaluated improvement of dyspnea and exercise tolerance. Baseline resting dyspnea was evaluated using Borg score (0 to 10). In order to evaluate the clinical bronchodilator response in the 6WT, we used the ATS statement (ref 20: 6MWD > 50 meters corrected in the text) associated to criterions tested on ref 5. This journal is available in PubMed since 2006 as J Bras Pneumol. The ATS statement refers that practice test is not needed in most clinical settings and that the reproducibility of the 6MWD is excellent. The manuscript was modified to better clarify this point. 3. Statistical analyses: Since Mann-Whitney test was used for quantitative data, it suggests that variables were not normally distributed. Spearman rank correlation would be preferred (instead of Pearson) and expression of the results as median [interquartile] would have been better. The effect of bronchodilation on pulmonary function tests would be evaluated using Wilcoxon test. It seems to me quite useless to compare the results of the two groups since these two groups have been selected based on their level of obstruction. I apologize for this mistake. Indeed, Spearman rank correlation test was used instead of Pearson. Tables 1/2/3 are now modified and data presented as median (interquartile). Additionally, the information regarding the effect of the bronchodilator on pulmonary function tests are now added. There were significant changes in VC, IC, FVC, FEV1, 6WTD and Borg Scale in both groups and a significant change in RV/TLC in severe group (p values are now added in tables 2/3). 4. Table 3. The correlations tested are meaningless. For instance, if the RV/TLC ratio decreases after bronchodilation, an increase in VC is expected (the absence of correlation would be amazing! (one limitation is that absolute volumes were evaluated by dilution technique) (Table 4) The correlation between the variation in VC and RV/TLC ratio was 0.7 in severe group. Unfortunately we were not able to use plethysmograph when the study was performed. Minor comments 1. Airflow limitation definition: since patients up to 76 years were enrolled, it is important to ensure that all patients had airflow limitation. What was the criterion defining airflow limitation? Tel/fax: marcusconde@hucff.ufrj.br
5 This is a very important point. Thank you for your comment. In the current study, we used the recommendations of GINA that considered FEV1 values below 80% to define function abnormality in patient with asthma. If we used the ATS/ERS consensus, [obstruction definition (FEV1/VC < 5 th percentile of predicted)] 2 patients did not fulfill the criterion for airflow limitation, although they had FEV1 values below 80%, respectively 79 an 69%. 2. Table 1: treatments should be given according to usual criteria, ICS, short-acting beta-agonists, long-acting, etc. Modified accordingly. 3. Table 1: X-Ray (normal/abnormal): it seems to me not useful since a normal X-Ray is expected in asthmatic patients Modified accordingly. 4. Table 1: 6-min walk distance should be given Overall the results should be simplified and should focus on the main results. : The results of 6-min walk test are now presented in a separate table (Table 3). Level of interest: An article of limited interest Quality of written English: Acceptable Statistical review: Yes, and I have assessed the statistics in my report. Declaration of competing interests: I declare that I have no competing interests Reviewer 2: Reviewer's report Title: Vital capacity and inspiratory capacitiy as additional parameters to evaluate bronchodilator response in asthmatics patients: a cross section study Version: 1 Date: 2 May 2012 Reviewer: Claudio Tantucci Reviewer's report: In a population of stable asthmatic patients with persistent airflow obstruction, after adequate wash out from bronchodilators, the Authors assessed the acute changes of FEV1 and FVC, but also those of IC and VC and their respective relationships with Tel/fax: marcusconde@hucff.ufrj.br
6 exercise capacity (m) and dyspnea (VAS) during a 6-minute walking test (6MWT) after the administration of 400 mcg of salbutamol (MDI). Despite a mild increment of FEV1, they found a significant and clinically relevant increase in FVC and VC in the group of patients with more severe baseline airway obstruction. Changes in VC were related to RV/TLC changes and were in agreement with improved exertional dyspnea. Thank you very much for your comments. General comments It is well known that in chronic asthma characterized by airway remodeling and mostly in severe chronic asthma where peripheral airways are more markedly involved, the acute change in FEV1 (so called flow response) although statistically significant often does not reach the cut-off for a positive broncho-reversibility test after SA bronchodilator. In contrast, a statistically significant and clinically positive acute change in FVC (so called volume response) after SA bronchodilator can be found in these patients: a functional behavior similar to that observed in most COPD patients. This is exactly what was found by the Authors who, in addition, showed similar changes in VC. No doubt that VC changes are more closely related to RV(plethysmographic) and RV/TLC (plethysmographic) ratio changes than FVC changes. The lung volume measurements performed by the Authors using a dilutional multibreath method and referred only in terms of TLC and RV/TLC ratio before and after bronchodilator, especially in patients with severe obstruction, are always difficult to interpret (because these volumes can decrease or increase), as well as their relationship with the changes of VC or FVC. Thank you very much for your comments. The variation of the RV/TCL ratio to analyze the rank correlation was used due to two reasons. First, the RV/TLC has been considered the static lung volume that was better correlated with the variation in spirometric parameters. Second, changes in TCL have not been expected after the bronchodilator in patients with asthma. Based on our data, the variation in TLC after the bronchodilator was not significant (p=0.80 in group 1 e p=0.38 in group 2 - additional data Table 2). Furthermore, the median values of TLC were normal in the 2 groups, both before and after bronchodilator. Reviewer The acute IC changes after bronchodilator are more interesting. In average, they seem significant (?) in the group with more severe asthma, but perhaps are not clinically relevant according to the predefined cut-off (?) in each patient. In any case the IC changes do not agree with the exertional dyspnea improvement, while the VC changes do. This is surprising and more than the agreement I would like to see the correlation between #VC and #IC vs #VAS. Tel/fax: marcusconde@hucff.ufrj.br
7 This is a very important point. In fact, IC presented significant changes in both moderate (p value = 0.02) and severe (p value < 0.01) patients. These data are not added in Table 2. Additionally the IC median values were different between the 2 groups (lower in severe obstruction patients both before and after bronchodilator). The correlation between VC and IC vs VAS was analyzed according to your suggestion and a poor correlation between VC and VAS (0.35) was found in severe obstruction patients. Additionally, we found a poor correlation between IC and VAS (0.28). These data were added in the text (results). Reviewer: Specific comments Background I wouldn t say that bronchodilators are the drug of choice for asthma management! This sentence is now modified according to your suggestion. Methods The technique used to measure lung volumes should be detailed in the Method section. The technique is now described in Method section. Which is the criterion for defining a positive bronchodilator FEV1 response: 12 % of predicted value or 12 % of baseline value plus 200 ml? Please, specify. The criterion for defining a positive bronchodilator FEV1 response is 12% of baseline value plus 200ml (ATS/ERS/2005). The text is now corrected. Results The RV values should be added in the Table 2. Modified as suggested. In Table 2 also the significance between pre- and post-bronchodilator values should be written for the different variables in both groups of asthmatics. Tel/fax: marcusconde@hucff.ufrj.br
8 Modified as suggested. Again, I would like to see the correlation between #VC and #IC vs #VAS shown in a figure. Modified as suggested. Level of interest: An article whose findings are important to those with closely related research interests Quality of written English: Needs some language corrections before being published Statistical review: No, the manuscript does not need to be seen by a statistician. Declaration of competing interests: I declare that I have no competing interests. Tel/fax: marcusconde@hucff.ufrj.br
PFT Interpretation and Reference Values
PFT Interpretation and Reference Values September 21, 2018 Eric Wong Objectives Understand the components of PFT Interpretation of PFT Clinical Patterns How to choose Reference Values 3 Components Spirometry
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with s Policy on Transparency and Publication of Clinical Study Data. The synopsis which is part of the
More informationAuthor's response to reviews
Author's response to reviews Title:Aclidinium improves exercise endurance, dyspnea, lung hyperinflation, and physical activity in patients with COPD: a randomized, placebo-controlled, crossover trial Authors:
More informationThe role of lung function testing in the assessment of and treatment of: AIRWAYS DISEASE
The role of lung function testing in the assessment of and treatment of: AIRWAYS DISEASE RHYS JEFFERIES ARTP education Learning Objectives Examine the clinical features of airways disease to distinguish
More informationBasic approach to PFT interpretation. Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic
Basic approach to PFT interpretation Dr. Giulio Dominelli BSc, MD, FRCPC Kelowna Respiratory and Allergy Clinic Disclosures Received honorarium from Astra Zeneca for education presentations Tasked Asked
More informationYuriy Feschenko, Liudmyla Iashyna, Ksenia Nazarenko and Svitlana Opimakh
2018; 7(1): 74-78 ISSN (E): 2277-7695 ISSN (P): 2349-8242 NAAS Rating: 5.03 TPI 2018; 7(1): 74-78 2018 TPI www.thepharmajournal.com Received: 11-11-2017 Accepted: 12-12-2017 Yuriy Feschenko Liudmyla Iashyna
More informationTeacher : Dorota Marczuk Krynicka, MD., PhD. Coll. Anatomicum, Święcicki Street no. 6, Dept. of Physiology
Title: Spirometry Teacher : Dorota Marczuk Krynicka, MD., PhD. Coll. Anatomicum, Święcicki Street no. 6, Dept. of Physiology I. Measurements of Ventilation Spirometry A. Pulmonary Volumes 1. The tidal
More informationTreatment. Assessing the outcome of interventions Traditionally, the effects of interventions have been assessed by measuring changes in the FEV 1
58 COPD 59 The treatment of COPD includes drug therapy, surgery, exercise and counselling/psychological support. When managing COPD patients, it is particularly important to evaluate the social and family
More informationClinical pulmonary physiology. How to report lung function tests
Clinical pulmonary physiology or How to report lung function tests Lung function testing A brief history Why measure? What can you measure? Interpretation/ reporting Examples and case histories Exercise
More informationIncreased difference between slow and forced vital capacity is associated with reduced exercise tolerance in COPD patients
Yuan et al. BMC Pulmonary Medicine 2014, 14:16 RESEARCH ARTICLE Open Access Increased difference between slow and forced vital capacity is associated with reduced exercise tolerance in COPD patients Wei
More informationDifference Between The Slow Vital Capacity And Forced Vital Capacity: Predictor Of Hyperinflation In Patients With Airflow Obstruction
ISPUB.COM The Internet Journal of Pulmonary Medicine Volume 4 Number 2 Difference Between The Slow Vital Capacity And Forced Vital Capacity: Predictor Of Hyperinflation In Patients With Airflow Obstruction
More informationSection 2: Multivariate or Multiple Domain Methods Aldurazyme Responder Index
Disclaimer: Presentation slides from the Rare Disease Workshop Series are posted by the Kakkis EveryLife Foundation, for educational purposes only. They are for use by drug development professionals and
More informationStudy No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationSupplementary Online Content
Supplementary Online Content Regan EA, Lynch DA, Curran-Everett D, et al; Genetic Epidemiology of COPD (COPDGene) Investigators. Clinical and radiologic disease in smokers with normal spirometry. Published
More informationAbnormalities of plethysmographic lung volumes in asthmatic children
Respiratory Medicine (2010) 104, 966e971 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Abnormalities of plethysmographic lung volumes in asthmatic children Bruno Mahut
More informationTitle:Benefits of Whole Body Vibration Training in Patients Hospitalised for COPD Exacerbations - a Randomized Clinical Trial
Author's response to reviews Title:Benefits of Whole Body Vibration Training in Patients Hospitalised for COPD Exacerbations - a Randomized Clinical Trial Authors: Timm Greulich (greulich@med.uni-marburg.de)
More informationPULMONARY FUNCTION TESTING. Purposes of Pulmonary Tests. General Categories of Lung Diseases. Types of PF Tests
PULMONARY FUNCTION TESTING Wyka Chapter 13 Various AARC Clinical Practice Guidelines Purposes of Pulmonary Tests Is lung disease present? If so, is it reversible? If so, what type of lung disease is present?
More informationStudy No.: Title: Rationale: Phase: Study Period Study Design: Centres: Indication: Treatment: Objectives : Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
More informationClinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene
Clinical and radiographic predictors of GOLD-Unclassified smokers in COPDGene Emily S. Wan, John E. Hokanson, James R. Murphy, Elizabeth A. Regan, Barry J. Make, David A. Lynch, James D. Crapo, Edwin K.
More informationAsthma Care in the Emergency Department Clinical Practice Guideline
Asthma Care in the Emergency Department Clinical Practice Guideline Inclusion: 1) Children 2 years of age or older with a prior history of wheezing, and 2) Children less than 2 years of age with likely
More informationSGRQ Questionnaire assessing respiratory disease-specific quality of life. Questionnaire assessing general quality of life
SUPPLEMENTARY MATERIAL e-table 1: Outcomes studied in present analysis. Outcome Abbreviation Definition Nature of data, direction indicating adverse effect (continuous only) Clinical outcomes- subjective
More informationPulmonary Function Testing: Concepts and Clinical Applications. Potential Conflict Of Interest. Objectives. Rationale: Why Test?
Pulmonary Function Testing: Concepts and Clinical Applications David M Systrom, MD Potential Conflict Of Interest Nothing to disclose pertinent to this presentation BRIGHAM AND WOMEN S HOSPITAL Harvard
More informationWhat do pulmonary function tests tell you?
Pulmonary Function Testing Michael Wert, MD Assistant Professor Clinical Department of Internal Medicine Division of Pulmonary, Critical Care, and Sleep Medicine The Ohio State University Wexner Medical
More informationContent Indica c tion Lung v olumes e & Lung Indica c tions i n c paci c ties
Spirometry Content Indication Indications in occupational medicine Contraindications Confounding factors Complications Type of spirometer Lung volumes & Lung capacities Spirometric values Hygiene &
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #51 (NQF 0091): Chronic Obstructive Pulmonary Disease (COPD): Spirometry Evaluation National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY
More informationIn patients with symptomatic COPD, desirable. Assessment of Bronchodilator Efficacy in Symptomatic COPD* Is Spirometry Useful?
Assessment of Bronchodilator Efficacy in Symptomatic COPD* Is Spirometry Useful? Denis E. O Donnell, MD, FCCP Bronchodilator therapy in COPD is deemed successful if it improves ventilatory mechanics to
More informationSpirometry: Introduction
Spirometry: Introduction Dr. Badri Paudel 1 2 GMC Spirometry Spirometry is a method of assessing lung function by measuring the volume of air the patient can expel from the lungs after a maximal expiration.
More informationSpirometry. Obstruction. By Helen Grim M.S. RRT. loop will have concave appearance. Flows decreased consistent with degree of obstruction.
1 2 Spirometry By Helen Grim M.S. RRT 3 4 Obstruction loop will have concave appearance. Flows decreased consistent with degree of obstruction. Volumes may be normal, but can decrease with severity of
More informationMSRC AIR Course Karla Stoermer Grossman, MSA, BSN, RN, AE-C
MSRC AIR Course Karla Stoermer Grossman, MSA, BSN, RN, AE-C Explain the importance of objective measures in the management of asthma Explain the different types of objective measures used in the management
More informationExercise 7: Respiratory System Mechanics: Activity 1: Measuring Respiratory Volumes and Calculating Capacities Lab Report
Exercise 7: Respiratory System Mechanics: Activity 1: Measuring Respiratory Volumes and Calculating Capacities Lab Report Pre-lab Quiz Results You scored 100% by answering 5 out of 5 questions correctly.
More informationPulmonary Function Testing The Basics of Interpretation
Pulmonary Function Testing The Basics of Interpretation Jennifer Hale, M.D. Valley Baptist Family Practice Residency Objectives Identify the components of PFTs Describe the indications Develop a stepwise
More informationTHE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable
THE CHALLENGES OF COPD MANAGEMENT IN PRIMARY CARE An Expert Roundtable This activity is supported by an educational grant from Sunovion Pharmaceuticals Inc. COPD in the United States Third leading cause
More informationHEART and LUNG. Heart failure and COPD Χ. ΑΔΑΜΟΠΟΥΛΟΣ ΓΝΘ «ΑΓΙΟΣ ΠΑΥΛΟΣ»
HEART and LUNG Heart failure and COPD Χ. ΑΔΑΜΟΠΟΥΛΟΣ ΓΝΘ «ΑΓΙΟΣ ΠΑΥΛΟΣ» Prevalence of concurrent HF and COPD 8 52 % of HF patients have concurrent COPD More common in male HF patients Prevalence increases
More informationCoexistence of confirmed obstruction in spirometry and restriction in body plethysmography, e.g.: COPD + pulmonary fibrosis
Volumes: IRV inspiratory reserve volume Vt tidal volume ERV expiratory reserve volume RV residual volume Marcin Grabicki Department of Pulmonology, Allergology and Respiratory Oncology Poznań University
More informationGuidance for Industry Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment
Guidance for Industry Chronic Obstructive Pulmonary Disease: Developing Drugs for Treatment DRAFT GUIDANCE This guidance document is being distributed for comment purposes only. Comments and suggestions
More informationbehaviour are out of scope of the present review.
explained about the test, a trial may be done before recording the results. The maneuver consists initially of normal tidal breathing. The subject then inhales to maximally fill the lungs. This is followed
More informationS P I R O M E T R Y. Objectives. Objectives 3/12/2018
S P I R O M E T R Y Dewey Hahlbohm, PA-C, AE-C Objectives To understand the uses and importance of spirometry testing To perform spirometry testing including reversibility testing To identify normal and
More informationChronic obstructive pulmonary disease
0 Chronic obstructive pulmonary disease Implementing NICE guidance June 2010 NICE clinical guideline 101 What this presentation covers Background Scope Key priorities for implementation Discussion Find
More informationSpirometry in primary care
Spirometry in primary care Wednesday 13 th July 2016 Dr Rukhsana Hussain What is spirometry? A method of assessing lung function Measures volume of air a patient can expel after a full inspiration Recorded
More informationDecramer 2014 a &b [21]
Buhl 2015 [19] Celli 2014 [20] Decramer 2014 a &b [21] D Urzo 2014 [22] Maleki-Yazdi 2014 [23] Inclusion criteria: Diagnosis of chronic obstructive pulmonary disease; 40 years of age or older; Relatively
More informationTORCH: Salmeterol and Fluticasone Propionate and Survival in COPD
TORCH: and Propionate and Survival in COPD April 19, 2007 Justin Lee Pharmacy Resident University Health Network Outline Overview of COPD Pathophysiology Pharmacological Treatment Overview of the TORCH
More informationThis is a cross-sectional analysis of the National Health and Nutrition Examination
SUPPLEMENTAL METHODS Study Design and Setting This is a cross-sectional analysis of the National Health and Nutrition Examination Survey (NHANES) data 2007-2008, 2009-2010, and 2011-2012. The NHANES is
More informationLecture Notes. Chapter 4: Chronic Obstructive Pulmonary Disease (COPD)
Lecture Notes Chapter 4: Chronic Obstructive Pulmonary Disease (COPD) Objectives Define COPD Estimate incidence of COPD in the US Define factors associated with onset of COPD Describe the clinical features
More informationSupplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Calverley P M A, Anzueto A R, Carter K, et
More informationLung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects
Lung Function Basics of Diagnosis of Obstructive, Restrictive and Mixed Defects Use of GOLD and ATS Criteria Connie Paladenech, RRT, RCP, FAARC Benefits and Limitations of Pulmonary Function Testing Benefits
More informationProductivity losses in chronic obstructive pulmonary disease a population-based survey.
Online supplement to Productivity losses in chronic obstructive pulmonary disease a population-based survey. Running head: Productivity losses in COPD. Authors: Marta Erdal, Department of Thoracic Medicine,
More informationCOMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP)
European Medicines Agency Pre-Authorisation Evaluation of Medicines for Human Use London, 19 February 2009 Doc. Ref. EMEA/CHMP/EWP/8197/2009 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) CONCEPT
More informationCOPD: Current Medical Therapy
COPD: Current Medical Therapy Angela Golden, DNP, FNP-C, FAANP Owner, NP from Home, LLC Outcomes As a result of this activity, learners will be able to: 1. List the appropriate classes of medications for
More informationSpirometry: an essential clinical measurement
Shortness of breath THEME Spirometry: an essential clinical measurement BACKGROUND Respiratory disease is common and amenable to early detection and management in the primary care setting. Spirometric
More informationFunctional Respiratory Imaging
Functional Respiratory Imaging (FRI) to assess the bioequivalence of inhaled medication Jan De Backer, MSc, PhD, MBA CEO BABE 2014 Functional Respiratory Imaging (FRI) FRI outcome parameters Added value
More informationPredictors of dynamic hyperinflation during the 6-minute walk test in stable chronic obstructive pulmonary disease patients
Original Article Predictors of dynamic hyperinflation during the 6-minute walk test in stable chronic obstructive pulmonary disease patients Rui Chen 1 *, Lin Lin 1 *, Jing-Wei Tian 1, Bin Zeng 2, Lei
More informationPDF of Trial CTRI Website URL -
Clinical Trial Details (PDF Generation Date :- Wed, 31 Oct 2018 11:13:48 GMT) CTRI Number Last Modified On 17/01/2015 Post Graduate Thesis Type of Trial Type of Study Study Design Public Title of Study
More informationThe Role of CPET (cardiopulmonary exercise testing) in Assessing Lung Disease in CF
The Role of CPET (cardiopulmonary exercise testing) in Assessing Lung Disease in CF Dr. Meir Mei-Zahav Kathy and Lee Graub CF Center Schneider CMCI 1 תאריך Exercise in CF You are probably quite sure that
More informationImpact of the new ATS/ERS pulmonary function test interpretation guidelines
Respiratory Medicine (2007) 101, 2336 2342 Impact of the new ATS/ERS pulmonary function test interpretation guidelines Mary Elizabeth Kreider a,, Michael A. Grippi a,b a Division of Pulmonary, Allergy,
More informationBronchodilator responsiveness in patients with COPD
Eur Respir J 28; 31: 742 75 DOI: 1.1183/931936.12967 CopyrightßERS Journals Ltd 28 Bronchodilator responsiveness in patients with COPD D.P. Tashkin*, B. Celli #, M. Decramer ", D. Liu +, D. Burkhart +,
More informationAssessment of reversibility of airway obstruction. disease. in patients with chronic obstructive airways. FEVy after salbutamol occurred in the
19 Regional Thoracic Unit, Fazakerley Hospital, Liverpool M Nisar M Walshaw J E Earis M G Pearson P M A Calverley Address for reprint requests: Dr P M A Calverley, Fazakerley Hospital, Liverpool, L9 7AL.
More informationASTRAZENECA v GLAXOSMITHKLINE
CASE AUTH/1986/4/07 ASTRAZENECA v GLAXOSMITHKLINE Symbicort and Seretide cost comparisons AstraZeneca complained about cost comparisons made by GlaxoSmithKline between AstraZeneca s Symbicort (budesonide/formoterol)
More informationAssessment of the Lung in Primary Care
Assessment of the Lung in Primary Care Andrew G Veale FRACP Auckland, New Zealand Presentation Cough (productive or dry) Haemoptysis Shortness of breath / dyspnea Wheeze (or noisy breathing) Chest pain
More informationDo current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma?
Respiratory Medicine (2006) 100, 458 462 Do current treatment protocols adequately prevent airway remodeling in children with mild intermittent asthma? Haim S. Bibi a,, David Feigenbaum a, Mariana Hessen
More informationIn order to diagnose lung diseases doctors
You Take My Breath Away Activity 5C NOTE: This activity is designed to follow You Really Are Full of Hot Air! Activity Objectives: After completing You Really Are Full of Hot Air! Activity 5B, students
More informationInterpreting pulmonary function tests: Recognize the pattern, and the diagnosis will follow
REVIEW FEYROUZ AL-ASHKAR, MD Department of General Internal Medicine, The Cleveland Clinic REENA MEHRA, MD Department of Pulmonary and Critical Care Medicine, University Hospitals, Cleveland PETER J. MAZZONE,
More informationQuality of life measurements and bronchodilator responsiveness in prescribing nebulizer therapy in COPD
Chronic Respiratory Disease 2008; 5: 13 18 http://crd.sagepub.com ORIGINAL PAPER Quality of life measurements and bronchodilator responsiveness in prescribing nebulizer therapy in COPD C Brophy 1, JA Kastelik
More informationDifferential diagnosis
Differential diagnosis The onset of COPD is insidious. Pathological changes may begin years before symptoms appear. The major differential diagnosis is asthma, and in some cases, a clear distinction between
More informationPhysiology of Asthma and Involvement of Small Airways Charles G. Irvin Ph.D.
Physiology of Asthma 1 Professor of Medicine, Pulmonary Medicine Director, Vermont Lung Center University of Vermont Pathophysiology of asthma - common wisdom 2 Jeffery and Haahtela BMC Pulmonary Medicine
More informationJOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES
JOINT CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) MANAGEMENT GUIDELINES Authors Dr Ian Benton Respiratory Consultant COCH Penny Rideal Respiratory Nurse COCH Kirti Burgul Respiratory Pharmacist COCH Pam
More informationAuthor's response to reviews
Author's response to reviews Title: Contribution of Interferon Gamma Release Assays testing to the Diagnosis of Latent Tuberculosis Infection in HIV-Infected Patients: A comparison of QuantiFERON Gold
More informationTitle: Prevalence and incidence of multiple sclerosis in central Poland,
Author s response to reviews Title: Prevalence and incidence of multiple sclerosis in central Poland, 2010-2014 Authors: Waldemar Brola (wbrola@wp.pl) Piotr Sobolewski (piotrsobolewski@poczta.onet.pl)
More informationOnline Data Supplement. Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey
Online Data Supplement Prevalence of Chronic Obstructive Pulmonary Disease in Korea: Results of a Population-based Spirometry Survey Dong Soon Kim, MD, Young Sam Kim MD, Kee Suk Chung MD, Jung Hyun Chang
More information2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY. MEASURE TYPE: Process
Quality ID #52 (NQF 0102): Chronic Obstructive Pulmonary Disease (COPD): Long-Acting Inhaled Bronchodilator Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL
More informationTitle: Exposure of bakery and pastry apprentices to airborne flour dust using PM2.5 and PM10 personal samplers
Author's response to reviews Title: Exposure of bakery and pastry apprentices to airborne flour dust using PM2.5 and PM10 personal samplers Authors: Estelle Mounier-Geyssant (estellemounier@yahoo.fr) Jean-Francois
More informationTitle: Associations of sitting time and occupation with metabolic syndrome in South Korean adults: a cross-sectional study
Author s response to reviews Title: Associations of sitting time and occupation with metabolic syndrome in South Korean adults: a cross-sectional study Authors: Jin Young Nam (jynam@yuhs.ac) Juyoung Kim
More informationJose Merino (Chair), Georg Roeggla, Tiago Villaneuva, John Fletcher. Amy Price, Elisabeth Loder. Jamie Kirhham (statisticians), Rubin Minhas
BMJ.2017.037871 "Efficacy of drugs used in preventive chemotherapy against soil-transmitted helminths: systematic review and network meta-analysis" *********************************************************************************************************
More informationThis clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data.
abcd Clinical Study Synopsis for Public Disclosure This clinical study synopsis is provided in line with Boehringer Ingelheim s Policy on Transparency and Publication of Clinical Study Data. The synopsis
More informationDLCO Webinar Q&A Dr. Christine Oropez answers post-presentation FAQs
DLCO Webinar Q&A Dr. Christine Oropez answers post-presentation FAQs If you re setting up bio controls, should they be measured at a specific window because of diurnal changes in DLCO? I would not necessarily
More informationPage 4. Line 7 and 8. Do these stats refer to children worldwide? Please clarify.
Reviewer s report Title: Management of severe acute malnutrition by cow milk in resource contraints settings: experience of the Nutritional Centre of the University Clinics of Graben Version: 0 Date: 27
More informationLung Pathophysiology & PFTs
Interpretation of Pulmonary Function Tests (PFTs) Course # 1612 2:00 5:00pm Friday February 22, 2013 Lung Pathophysiology & PFTs Mark F. Sands MD, FCCP, FAAAAI Division of Allergy, Immunology & Rheumatology
More informationCorrelation of the Ratio of Upper Third to Lower Third Circumferences of the Chest with Obstructive Pattern in Spirometry
Original Article 2015 NRITLD, National Research Institute of Tuberculosis and Lung Disease, Iran ISSN: 1735-0344 TANAFFOS Correlation of the Ratio of Upper Third to Lower Third Circumferences of the Chest
More informationEffect of N-Acetylcysteine on Air Trapping in COPD. A Randomized Placebo-Controlled Study
CHEST Effect of N-Acetylcysteine on Air Trapping in COPD A Randomized Placebo-Controlled Study David Stav, MD; and Meir Raz, MD Original Research COPD Background: FEV 1 is used for the classification of
More informationnormal and asthmatic males
Lung volume and its subdivisions in normal and asthmatic males MARGARET I. BLACKHALL and R. S. JONES1 Thorax (1973), 28, 89. Institute of Child Health, University of Liverpool, Alder Hey Children's Hospital,
More informationPULMONARY FUNCTION. VOLUMES AND CAPACITIES
PULMONARY FUNCTION. VOLUMES AND CAPACITIES The volume of air a person inhales (inspires) and exhales (expires) can be measured with a spirometer (spiro = breath, meter = to measure). A bell spirometer
More informationPEER REVIEW HISTORY ARTICLE DETAILS VERSION 1 - REVIEW
PEER REVIEW HISTORY BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (see an example) and are provided with free text boxes to
More informationPULMONARY FUNCTION TESTS
Chapter 4 PULMONARY FUNCTION TESTS M.G.Rajanandh, Department of Pharmacy Practice, SRM College of Pharmacy, SRM University. OBJECTIVES Review basic pulmonary anatomy and physiology. Understand the reasons
More informationClinical Study Bronchial Responsiveness in Patients with Restrictive Spirometry
BioMed Research International Volume 2013, Article ID 498205, 5 pages http://dx.doi.org/10.1155/2013/498205 Clinical Study Bronchial Responsiveness in Patients with Restrictive Spirometry Jean I. Keddissi,
More informationVA/DoD Clinical Practice Guideline Management of COPD Pocket Guide
VA/DoD Clinical Practice Guideline Management of COPD Pocket Guide MODULE A: MAAGEMET OF COPD 1 2 Patient with suspected or confirmed COPD presents to primary care [ A ] See sidebar A Perform brief clinical
More informationPulmonary Function Testing
Pulmonary Function Testing Let s catch our breath Eddie Needham, MD, FAAFP Program Director Emory Family Medicine Residency Program Learning Objectives The Astute Learner will: Become familiar with indications
More informationChoosing an inhaler for COPD made simple. Dr Simon Hart Castle Hill Hospital
Choosing an inhaler for COPD made simple Dr Simon Hart Castle Hill Hospital 1 Declaration of interests I have received speaker fees, sponsorship to attend conferences, and funding for research from companies
More informationTriennial Pulmonary Workshop 2012
Triennial Pulmonary Workshop 2012 Rod Richie, M.D., DBIM Medical Director Texas Life Insurance Company, Waco, TX EMSI, Waco, TX Lisa Papazian, M.D., DBIM Assistant Vice President and Medical Director Sun
More informationVariability of within-breath reactance in COPD patients and its association with dyspnoea
ORIGINAL ARTICLE COPD Variability of within-breath reactance in COPD patients and its association with dyspnoea Bernt B. Aarli 1,2, Peter M.A. Calverley 3, Robert L. Jensen 4, Tomas M.L. Eagan 1,2, Per
More informationPFIZER INC. THERAPEUTIC AREA AND FDA APPROVED INDICATIONS: See USPI.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.
More informationTitle: Home Exposure to Arabian Incense (Bakhour) and Asthma Symptoms in Children: A Community Survey in Two Regions in Oman
Author's response to reviews Title: Home Exposure to Arabian Incense (Bakhour) and Asthma Symptoms in Children: A Community Survey in Two Regions in Oman Authors: Omar A Al-Rawas (orawas@squ.edu.om) Abdullah
More informationDATE: 29 Aug 2012 CONTEXT AND POLICY ISSUES
TITLE: Tiotropium Compared with Ipratropium for Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease: A Review of the Clinical Effectiveness DATE: 29 Aug 2012 CONTEXT AND POLICY ISSUES
More informationGuideline for the Diagnosis and Management of COPD
Guideline for the Diagnosis and Management of COPD Introduction Chronic obstructive pulmonary disease (COPD) is a respiratory disorder largely caused by smoking. It is characterized by progressive, partially
More informationThe Aging Lung. Sidney S. Braman MD FACP FCCP Professor of Medicine Brown University Providence RI
The Aging Lung Sidney S. Braman MD FACP FCCP Professor of Medicine Brown University Providence RI Is the respiratory system of the elderly different when compared to younger age groups? Respiratory Changes
More informationPulmonary Rehabilitation in Chronic Lung Disease; Components and Organization. Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept.
Pulmonary Rehabilitation in Chronic Lung Disease; Components and Organization Prof. Dr. Müzeyyen Erk Cerrahpaşa Medical Faculty Chest Disease Dept. Plan Chronic Respiratory Disease Definition Factors Contributing
More informationPerforming a Methacholine Challenge Test
powder for solution, for inhalation Performing a Methacholine Challenge Test Provocholine is a registered trademark of Methapharm Inc. Copyright Methapharm Inc. 2016. All rights reserved. Healthcare professionals
More informationKnown Allergies: Shellfish. Symptoms: abdominal pain, nausea, diarrhea, or vomiting. congestion, trouble breathing, or wheezing.
CSTAR CASE STUDIES: BLOCK B Asthma or COPD? Setting: Walk in clinic. Dan: I havi g that cough thi g agai HPI: Dan is a 49-year-old male teacher who reports having had episodes of cough with mucus production
More information6- Lung Volumes and Pulmonary Function Tests
6- Lung Volumes and Pulmonary Function Tests s (PFTs) are noninvasive diagnostic tests that provide measurable feedback about the function of the lungs. By assessing lung volumes, capacities, rates of
More informationDiagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma
ORIGINAL RESEARCH Diagnostic value of post-bronchodilator pulmonary function testing to distinguish between stable, moderate to severe COPD and asthma Daphne C Richter 1 James R Joubert 1 Haylene Nell
More informationInternational Journal of Scientific & Engineering Research, Volume 7, Issue 4, April ISSN
International Journal of Scientific & Engineering Research, Volume 7, Issue 4, April-2016 1644 Interpretation of Bronchodilator Response for Assessment of Airway Obstruction. Dr.S. meenakshi ABSTRACT:
More informationTitle: Sports activity and combined use of snus and cigarette smoking among young males in Finland in
Author's response to reviews Title: Sports activity and combined use of snus and cigarette smoking among young males in Finland in 1999-2010 Authors: Ville M Mattila (ville.mattila@uta.fi) Susanna Raisamo
More information